AUTHORS
Xiao-Dong Mo, MD, Er-Lie Jiang, MD2, He Huang, MD, PhD3, Xinchuan Chen, MD, PhD4, Yi Luo5, Chengwei Luo, PhD6, Yicheng Zhang7, Yuhua Li, MD, PhD8, Nainong Li, MD9, Linghui Xia10, Ming Jiang, MS11, Jia Chen Sr, MD12, Feng Chen, MD13, Sujun Gao14, Zhao Liang15, Yi Liu16, Dongqin Yang17, Yimin Chen18, Chen Wang19, Qingli Zuo20, Depei Wu Sr, MD21
AFFILIATIONS
1 Peking University People's Hospital, Beijing, China
2 Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, China
3 The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
4 West China Hospital of Sichuan University, Chengdu, China
5 The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
6 Guangdong Provincial People's Hospital, Guangzhou, China
7 Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
8 Zhujiang Hospital of Southern Medical University, Guangzhou, China
9 Fujian Medical University Union Hospital, Fuzhou, China
10 Union Hospital Affiliated to Tongji Hospital of Huazhong University of Science and Technology, Wuhan, China
11 The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China
12 The First Affiliated Hospital of Soochow University, Suzhou, China
13 The First Affiliated Hospital of Soochow University, Suzhou, China
14 The First Hospital of Jilin University, Changchun, China
15 Zhujiang Hospital of Southern Medical University, Guangzhou, China
16 Abbisko Therapeutics Co.,Ltd, Shanghai, China
17 Abbisko Therapeutics Co.,Ltd, Shanghai, China
18 Abbisko Therapeutics Co.,Ltd, Shanghai, China
19 Abbisko Therapeutics Co.,Ltd, Shanghai, China
20 Abbisko Therapeutics Co.,Ltd, Shanghai, China
21 The First Affiliated Hospital of Soochow University, Suzhou, China
ABSTRACT
Background
Chronic graft-versus-host disease (cGVHD) remains a leading cause of late morbidity and mortality after allogeneic hematopoietic stem cell transplantation, and durable disease control is difficult after multiple systemic therapies. Colony-stimulating factor 1 receptor (CSF-1R)-dependent macrophages contribute to chronic inflammation and fibrosis in cGVHD. Pimicotinib (Pimi) is an oral, highly selective small-molecule CSF-1R inhibitor. Preliminary results from ABSK021-201 presented at ASH 2024 demonstrated rapid clinical activity. Here, we report mature follow-up focusing on primary endpoint, response durability, failure-free survival (FFS), sustained organ-specific benefit, corticosteroid reduction, symptoms, and longer-term safety at the recommended dose of 20 mg once daily, supporting pivotal study development.
Methods
ABSK021-201 (NCT06186804) is an ongoing multicenter, open-label phase 2 study in adults with cGVHD after at least 1 prior systemic therapy. Patients received Pimi 5 to 25 mg once daily in 28-day cycles. The primary efficacy endpoint was investigator-assessed overall response rate (ORR) through cycle 7 day 1 (C7D1) using the 2014 NIH Consensus Criteria. Secondary endpoints included duration of response (DOR), time to response (TTR), FFS, organ responses, corticosteroid use, modified Lee Symptom Scale (mLSS), and safety.
Results
As of June 12, 2026, 68 patients had received Pimi, including four dose levels were evaluated: 5 mg (n=1), 10 mg (n=24), 20 mg (n=40) and 25 mg (n=3). In the 20-mg cohort, 40 patients were treated, 39 were response evaluable, and 10 remained on treatment. The median follow-up time was 25.7months. Median age was 36.5 years; 55.0% had severe cGVHD, the median number of involved organs was 4, and 77.5% had received prior ruxolitinib. Median treatment exposure was 9.2 months (maximum, 31.3), and 40.0% were treated for at least 12 months.
At 20 mg, ORR through C7D1 was 64.1% (25/39; 95% CI, 47.2-78.8), with a median TTR of 0.69 months. Responses were durable: median DOR was 14.4 months (95% CI, 10.0-not estimable), and 84.0% (21/25) and 64.0% (16/25) of responders maintained response for at least 6 and 12 months, respectively. Median FFS was 11.4 months (95% CI, 5.5-22.2), with a 12-month FFS rate of 49.2%. At C7D1, responses were observed in 54.5% (6/11) of patients with at least 3 prior systemic therapies and 53.3% (16/30) of those previously treated with ruxolitinib. Responses spanned inflammatory and fibrosis-associated manifestations, including esophagus (57.1%, 8/14), joints/fascia (52.6%, 10/19), skin (30.8%, 8/26), and lung (20.0%, 4/20); 70.0% (7/10) of joint/fascia responders maintained response for at least 12 months. Among patients with lung involvement, 20.0% (4/20) had a greater than 10% increase in percent-predicted FEV1 and 75.0% (15/20) had at least a 1-point improvement in Lung Function Score by NIH. Among 19 patients receiving corticosteroids at baseline, 57.9% achieved at least a 50% dose reduction or discontinued corticosteroids. A reduction of at least 7 points in mLSS occurred in 41.0% (16/39), with a median cumulative duration of improvement of 54.5 weeks.
With extended exposure to 20mg QD cohort, no new safety signals emerged. Treatment-Related Adverse Events (TRAEs) occurred in 80.0% (32/40) of patients, were grade ≥ 3 in 20.0% (8/40), and were serious in 7.5% (3/40). The most common TRAEs (≥20%) including AST increased (45.0%), ALT increased (32.5%), LDH increased (27.5%), CPK increased (22.5%), GGT increased (22.5%) and ALP increased (22.5%). Common TRAEs were predominantly asymptomatic laboratory enzyme elevations consistent with CSF-1R inhibition and prior Pimi experience and were not associated with clinical evidence of hepatic or muscle injury. No individual grade ≥ 3 TRAEs occurred in more than 7.5% of patients. TRAEs led to dose reduction and interruption in 5.0% and 17.5%, respectively, and no TRAEs led to treatment discontinuation or death. Treatment-Emergent Adverse Event (TEAEs) led to treatment discontinuation in 7.5%.
Conclusions
With mature follow-up, once-daily oral Pimi demonstrated durable responses, prolonged FFS, sustained benefit across inflammatory and fibrosis-associated organ manifestations, and meaningful corticosteroid-sparing and symptom improvement. Longer treatment exposure did not reveal new safety signals, supporting further investigation of Pimi as a long-term treatment option for relapsed or refractory cGVHD.
DISCLOSURES
Jia Chen Sr, MD: No relevant conflicts of interest to declare.